Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
Three Biotechs That Are Top Takeover Targets
01:55pm, Monday, 18'th May 2026
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
08:49am, Friday, 25'th Jul 2025
INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Bost
Lilly and Verve announce expiration of Verve tender offer
08:00am, Thursday, 24'th Jul 2025
INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and outst
3 Bullish Biotech Stocks With Explosive Growth Trends
11:03am, Monday, 21'st Jul 2025
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp mo
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
01:07pm, Friday, 20'th Jun 2025
Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicin
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
09:15am, Friday, 20'th Jun 2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of V
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
10:35am, Wednesday, 18'th Jun 2025
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
01:16pm, Tuesday, 17'th Jun 2025
VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.
VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders
11:11am, Tuesday, 17'th Jun 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareho
Why Verve Therapeutics Stock Is Skyrocketing Today
11:05am, Tuesday, 17'th Jun 2025
Shares of Verve Therapeutics (VERV 76.24%) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday.
Biotech Stock Surging on Billion-Dollar Buyout
09:53am, Tuesday, 17'th Jun 2025
Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid news that peer Eli Lilly (LLY) will buy the company for $10.50 per share, or roughly $1.3 billion.
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
09:14am, Tuesday, 17'th Jun 2025
Verve Therapeutics stock nearly doubled Tuesday after Eli Lilly agreed to buy the gene-editing company for up to $1.3 billion.
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to le
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
07:55am, Tuesday, 17'th Jun 2025
Eli Lilly agreed to acquire Verve Therapeutics for approximately $1 billion up front, adding a potential treatment for cardiovascular disease to its portfolio.
